Sun Pharma Q4 Results FY24-25: Revenue Rs.1.29 Lakh Cr, PAT Rs.21,499 Cr

Synopsis:

Sun Pharma posted consolidated revenue of Rs.1.29 lakh crore and net profit of Rs.21,499 crore in Q4 FY25. For FY25, total income reached Rs.5.45 lakh crore and PAT stood at Rs.1.09 lakh crore, reflecting strong growth in core operations.


Sun Pharma delivered a robust financial performance in Q4 FY25, led by consistent growth in both domestic and international markets. The company’s consolidated revenue rose 8% year-on-year to Rs.1,29,588 crore, while net profit increased 18.6% to Rs.21,499 crore. For the full year, Sun Pharma reported Rs.5,25,784 crore in revenue and Rs.1,09,290 crore in net profit. Margin expansion and increased R&D investments highlighted the company’s strategic focus on innovation and specialty drugs.

Sun Pharmaceutical Ind L

Trade

1782.22.09 (0.11 %)

Updated - 05 June 2026
1802.90day high
DAY HIGH
1779.00day low
DAY LOW
2095353
VOLUME (BSE)

Key Highlights / Quick Insights

  • Q4 FY25 Revenue: Rs.1,29,588 crore, up 8% YoY

  • Q4 FY25 PAT: Rs.21,499 crore, up 18.6% YoY

  • FY25 Revenue: Rs.5,25,784 crore, up 8.4% YoY

  • FY25 PAT: Rs.1,09,290 crore, up 14% YoY

  • FY25 EBITDA (Est.): Rs.1,44,300 crore (approx. EBITDA margin ~27.4%)

  • EPS (FY25): Rs.45.6 vs Rs.39.9 in FY24

  • Dividend: Final dividend of Rs.5.50 per share declared (Total FY25: Rs.16.00 per share)

Quarterly – Sun Pharma Q4 Results FY24-25

Particulars

Q4 FY25 (Rs. Cr)

Q4 FY24 (Rs. Cr)

YoY Change

Total Income

1,35,717

1,25,888

+7.8%

EBITDA (Est.)

36,160

29,171

+23.9%

EBITDA Margin (%)

~28.5%

~23.2%

+530 bps

Profit Before Tax

32,544

28,155

+15.6%

Profit After Tax

21,499

18,573*

+15.8%

PAT Margin (%)

15.8%

14.8%

+100 bps

EPS (Rs.)

9.0

7.7*

+16.9%

*Estimate based on FY24 quarterly PAT average

   

Segment Highlights

Sun Pharma operates in a single reportable segment — Pharmaceuticals — with strong performance across geographies.

  • India Business: Maintains leadership in branded generics

  • US Market: Growth driven by specialty and generics

  • Emerging Markets: Continued traction in Asia and LATAM

  • R&D Spend: Rs.7,904 crore in FY25, reflecting innovation push

Sector Expectations for Sun Pharma Q4 Results FY24-25

Market expectations were optimistic, anticipating consistent growth in branded generics and margin improvement. Sun Pharma outperformed on profitability, aided by reduced forex losses and controlled expenses. The company’s performance was broadly above street estimates, especially on earnings and margin fronts.

Management Commentary

The Board has proposed a final dividend of Rs.5.50 per share, raising the total FY25 payout to Rs.16.00. Sun Pharma also announced board-level changes, including the appointment of Ms. Vidhi Shanghvi as Whole-time Director and the retirement of Mr. Sudhir Valia.

Stay updated on Q4 FY25 earnings via our Quarterly Results Calendar featuring real-time schedules, forecasts, and financial summaries.

Source: The results above are derived from Sun Pharmaceutical Industries Ltd’s official BSE filings and financial disclosures as of May 22, 2025.

Share this article: 

Published Date : 22 May 2025

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text